
ACET
Healthcare · Biotechnology · $26.0M market cap
$2.78-0.15 (-5.1%)Nov 13, 4:02 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -26.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | After the close | -1.56 | -1.76 | -12.8% |
| Aug 5, 2026 | After the close | -2.43 | -1.99 | +18.1% |
| May 13, 2026 | After the close | -3.08 | -1.88 | +39.0% |
| Mar 5, 2026 | Time not confirmed | -0.19 | -2.94 | -1422.5% |
| Nov 5, 2025 | After the close | -0.26 | -0.29 | -11.5% |
| Aug 7, 2025 | After the close | -0.32 | -0.34 | -6.3% |
| May 6, 2025 | After the close | -5.38 | -4.96 | +7.8% |
| Mar 17, 2025 | Before the open | -0.35 | -0.32 | +9.9% |
| Nov 6, 2024 | After the close | -5.33 | -5.44 | -2.1% |
| Aug 13, 2024 | Before the open | -5.84 | -5.28 | +9.6% |
| May 14, 2024 | After the close | -6.28 | -5.60 | +10.8% |
| Mar 19, 2024 | After the close | -0.69 | -0.69 | 0.0% |
| Nov 8, 2023 | After the close | -12.00 | -18.56 |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a…
| -54.7% |
| Aug 9, 2023 | After the close | -6.81 | -12.00 | -76.2% |
| May 9, 2023 | After the close | -10.53 | -11.52 | -9.4% |
| Mar 15, 2023 | After the close | -0.28 | -0.72 | -157.1% |
| Nov 8, 2022 | After the close | -8.49 | -8.48 | +0.1% |
| Aug 10, 2022 | Before the open | -7.47 | -8.96 | -19.9% |
| May 12, 2022 | After the close | -6.08 | 1.60 | +126.3% |
| Mar 15, 2022 | After the close | -0.42 | -0.47 | -11.9% |
| Nov 10, 2021 | After the close | -6.82 | -7.04 | -3.2% |
| Aug 12, 2021 | After the close | -8.45 | -5.44 | +35.6% |
| May 17, 2021 | Before the open | -0.49 | -0.82 | -67.3% |
| Mar 11, 2021 | After the close | -13.36 | -7.36 | +44.9% |
| Nov 5, 2020 | After the close | -12.32 | -12.00 | +2.6% |
| Jul 30, 2020 | Before the open | -1.74 | -1.05 | +39.7% |
| May 7, 2020 | Before the open | -2.36 | -1.33 | +43.6% |
| Mar 12, 2020 | Before the open | -4.39 | -5.53 | -26.0% |
| Nov 5, 2019 | Before the open | -3.76 | -4.76 | -26.6% |
| Aug 14, 2019 | Before the open | -2.74 | -3.57 | -30.3% |
| May 15, 2019 | Before the open | -2.52 | -2.66 | -5.6% |
| Mar 18, 2019 | After the close | -2.38 | -1.47 | +38.2% |
| Nov 13, 2018 | Before the open | -3.53 | -2.10 | +40.5% |
| Aug 9, 2018 | Before the open | -2.94 | -3.36 | -14.3% |
| May 10, 2018 | After the close | -1.71 | -3.22 | -88.3% |
| Mar 29, 2018 | After the close | -7.21 | -35.77 | -396.1% |